Cyteir Therapeutics $133.2 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $133.2 million initial public offering of 7,400,000 shares of common stock of Cyteir Therapeutics, Inc. Cyteir’s common stock is listed on the Nasdaq Global Select Market under the symbol “CYT.”
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates.
The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Moses Farzan Nekou, Christian Knoble and Gil Savir. Counsel Kiara L. Rankin provided tax advice. Partner David R. Bauer and associates Christopher C. Woller and Marisa Elena Bannon provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.